Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
  • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
  • C07B59/008—Peptides; Proteins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
  • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Definitions

• the invention relates generally to imaging agents that bind to human epidermal growth factor receptor type 2 (HER2) and methods for making and using such agents.
• HER2 human epidermal growth factor receptor type 2
• HER2 Human epidermal growth factor receptor type 2
• HER2 is a transmembrane protein and a member of erbB family of receptor tyrosine kinase proteins.
• HER2 is a well-established tumor biomarker that is over-expressed in a wide variety of cancers, including breast, ovarian, lung, gastric, and oral cancers. Therefore, HER2 has great value as a molecular target and as a diagnostic or prognostic indicator of patient survival, or a predictive marker of the response to antineoplastic surgery.
• PET and SPECT imaging of HER2 provide high sensitivity, high spatial resolution. PET imaging of HER2 also provides strong quantification ability.
• HER2-PET and HER2-SPECT are particularly useful in real-time assays of overall tumor HER2 expression in patients, identification of HER2 expression in tumors over time, selection of patients for HER-targeted treatment (e.g., trastuzumab-based therapy), prediction of response to therapy, evaluation of drug efficacy, and many other applications.
• HER-targeted treatment e.g., trastuzumab-based therapy
• trastuzumab-based therapy e.g., trastuzumab-based therapy
• prediction of response to therapy e.g., evaluation of drug efficacy
• evaluation of drug efficacy e.g., trastuzumab-based therapy
• no PET or SPECT-labeled HER2 ligands have been developed that have a chemistry and exhibit in vivo behaviors which would be suitable for clinical applications.
• Naturally occurring Staphylococcal protein A comprises domains that form a three-helix structure (a scaffold) that binds to the fragment, crystallizable region (Fc) of immunoglobulin isotype G (IgG).
• Certain polypeptides, derived from the Z- domain of protein A contain a scaffold composed of three a-helices connected by loops. Certain amino acid residues situated on two of these helices constitute the binding site for the Fc region of IgG.
• Alternative binder molecules have been prepared by substituting surface-exposed amino acid residues (13 residues) situated on helices 1 and 2, to alter the binding ability of these molecules.
• HER2 binding molecules or HER2 binders are examples of HER2 binding molecules or HER2 binders.
• HER2 binders have been labeled with PET or SPECT-active radionuclides.
• PET and SPECT-labeled binders provide the ability to measure in vivo HER2 expression patterns in patients and would therefore aid clinicians and researchers in diagnosing, prognosing, and treating HER2- associated disease conditions.
• HER2 binding Affibody® molecules radiolabeled with the PET-active radionucleide, 18 F, have been evaluated as imaging agents for malignant tumors that over express HER2.
• HER2 binding Affibody® molecules conjugated with 99m Tc via the chelators such as maGGG (mercaptoacetyltriglycyl), CGG (cysteine-diglycyl), CGGG (SEQ ID NO: 6) (cysteine-triglycyl) or A A3, have also been used for diagnostic imaging. The binding of these molecules to target HER2 expressing tumors has been demonstrated in mice.
• the signal-generating 18 F group is introduced to the Affibody® through a thiol-reactive maleimide group.
• the thiol reactive maleimide group is prepared using a multi-step synthesis after 18 F incorporation. However, this chemistry only provides a low radiochemical yield.
• the conjugation of 99m Tc with the Affibody® is a multistep process.
• compositions of the invention are a new class of imaging agents that are capable of binding specifically to HER2 or variants thereof.
• the imaging agent composition comprises an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID. No 2 or a conservative variant thereof, conjug ated with a 99m Tc via a diaminedioxime chelator.
• the diaminedioxime chelator may comprise Pn216, cPn216, Pn44, or derivatives thereof.
• the isolated polypeptide binds specifically to HER2 or variants thereof.
• the imaging agent composition comprises an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID. No 2 or a conservative variant thereof, conjug ated with 67 Ga or 68 Ga via a NOTA chelator.
• the isolated polypeptide binds specifically to HER2 or variants thereof.
• the imaging agent composition comprises an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID. No 2 or a conservative variant thereof, conjugated with an Al 18 F-NOTA chelate.
• the isolated polypeptide binds specifically to HER2 or variants thereof.
• the imaging agent composition comprises an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID. No 2 or a conservative variant thereof, conjugated with 18 F via a linker.
• the linker comprises a group derived from an aminoxy group, an azido group, or an alkyne group.
• the isolated polypeptide binds specifically to HER2 or variants thereof.
• the imaging agent composition comprises an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID. No 2 or a conservative variant thereof, conjugated with 18 F via an isotopic fluorine exchange chemistry.
• the isolated polypeptide binds specifically to HER2 or variants thereof.
• an imaging agent composition as described herein comprises (i) providing an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID No. 2 or a conservative variant thereof; and (ii) reacting a diaminedioxime chelator with the polypeptide to form a chelator conjugated polypeptide.
• the method comprises (i) providing an isolated polypeptide comprising SEQ. ID No. 1 , SEQ. ID No.
• linker may comprise an aminoxy group, an azido group, or an alkyne group.
• the method comprises (i) providing an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID No. 2 or a conservative variant thereof; (ii) reacting the polypeptide with a NOTA- chelator to form, respectively, a NOTA-chelator conjugated polypeptide and (iii) reacting the NOTA- chelator conjugated polypeptide with an Al 18 F moiety to form, a Al 18 F-NOTA chelator conjugated polypeptide.
• the method comprises (i) providing an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID No. 2 or a conservative variant thereof; (ii) reacting the polypeptide with a silicon fluoride (e.g. [ 19 F]-silicon fluoride)-containing moiety to form a silicon fluoride conjugated polypeptide; and (iii) reacting the silicon fluoride conjugated polypeptide with an 18 F moiety to form an 18 F-silicon fluoride conjugated polypeptide.
• a silicon fluoride e.g. [ 19 F]-silicon fluoride
• FIGs. 1A and IB are graphs of the surface plasmon resonance (SPR) of the binding affinity of two anti-HER2 polypeptides, Z477 (SEQ. ID No. 3) and (Z477) 2 (SEQ. ID No. 5), respectively, at eight different concentrations, to human HER2.
• SPR surface plasmon resonance
• FIGs. 2 A and FIG. 2B are graphs of the qualitative flow cytometry of C6 (rat glioma, control) and human anti-HER2 antibody to SKOV3 (human ovarian carcinoma) respectively.
• FIG. 2C shows a bar chart for Her2 receptors per cell for SKOV3 and C6 cell lines.
• FIG. 3 is a bar graph of ELISA assays for Her2 with respect to a panel of tumor types SKOV3 2-1, SKOV3 3-1, SKOV3 3-4, with respect to SKOV3 cells, and blank.
• FIG. 4 is a reverse phase HPLC gamma chromatogram of m Tc labeled Z00477 (SEQ. ID No. 3).
• FIG. 5A is a size exclusion HPLC gamma chromatogram of aggregated 99m Tc(CO) 3 (His6)Z00477 (SEQ. ID. No. 4) ('His6' disclosed as SEQ ID NO: 7) at pH 9.
• FIG. 5B a size exclusion HPLC gamma chromatogram of non aggregated 99m Tc(CO) 3 (His6)Z00477 ('His6' disclosed as SEQ ID NO: 7) labeled Affibody® standard.
• FIG. 6 is a graph of biodistribution profile of Z00477 (SEQ. ID No. 3) in blood, tumor, liver, kidney and spleen samples from SKOV3 tumor bearing mice, including the tumonblood ratio over time.
• FIG. 7 is a diagram of the chemical structure for a Mal-cPN216 linker.
• FIG. 8A is a graph of the electrospray ionization time of flight mass spectrum (ESI-TOF-MS) and FIG. 8B is a graph of mass deconvolution result for the purified Z00477 (SEQ. ID No. 3)-cPN216.
• FIG. 9 is a reverse phase HPLC gamma trace chromatogram for Z02891- cPN216 (SEQ. ID No. 2) labeled with 99m Tc.
• FIG. 10 is a graph of the biodistribution profile of Z02891 (SEQ. ID No. 2) labeled with 99m Tc via cPN216 ( ID, % injected dose)) in blood, liver, kidneys, spleen, and tail samples from SKOV3 tumor bearing mice.
• FIG. 11 is a graph of the biodistribution profile of Z02891 (SEQ. ID No. 2) labeled with 99m Tc via cPN216 ( ID, % injected dose) in tumor, blood, liver, kidneys , bladder/urine, tail, intestine and spleen samples from SKOV3 tumor bearing mice.
• FIG. 12 is a graph of the biodistribution profile for Z02891 (SEQ. ID No. 2) in SKOV3 tumor bearing mice showing the tumor: blood ratio.
• FIG. 13A and 13B are diagrams of the chemical structures for Boc -protected malimide-aminoxy (Mal-AO-Boc) and malimide-aminoxy (Mal-AO) linkers.
• 13 A is the chemical structure for tert-butyl 2-(2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l- yl)ethylamino)-2-oxoethoxycarbamate (Mal-AO-Boc)
• 13B is the chemical structure for 2-(aminooxy)-N-(2-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l- yl)ethyl)acetamide hydrochloride (Mal-AO.HCl).
• FIG. 14A is the reverse phase HPLC chromatogram of Z00342 (SEQ. ID No. 1) starting material and 14B is the reverse phase HPLC chromatogram of the purified Z00342 (SEQ. ID No. l)-AO imaging agent composition, both analyzed at 280 nm.
• FIG. 15 is the reverse phase HPLC gamma chromatogram for the crude
• FIG. 16 is a graph of the biodistribution profile ( ID, % injected dose) of the Z02891 (SEQ. ID No. 2) polypeptide labeled with 18 F from SKOV3-tumored animals.
• FIG. 17 is a graph of the biodistribution profile of Z02891 (SEQ. ID No. 2)
• polypeptide labeled with F ID, % injected dose
• tumor blood ratio from SKOV3-tumored animals.
• FIG. 18 is bar graph of the biodistribution profile ( ID, % injected dose) of 18 F labeled Z00342 (SEQ. ID No. 1) and 18 F labeled Z02891 (SEQ. ID No. 2) in blood, tumor, liver, kidneys, spleen and bone samples.
• FIG. 19 is a diagram of the chemical structure of the Mal-NOTA linker.
• FIG. 20A is a graph of the electrospray ionization time of flight mass spectrum (ESI-TOF-MS), and 20B is a graph of the ESI-TOF-MS mass deconvolution result for Z00477 (SEQ. ID No. 3)-NOTA.
• ESI-TOF-MS electrospray ionization time of flight mass spectrum
• FIG. 21 is a graph of the reverse phase HPLC gamma trace for the crude reaction mixture of 67 Ga-labeled Z00477 (SEQ. ID No. 3)-NOTA after 1 hour of reaction.
• FIG. 22 is a graph of the reverse phase HPLC gamma trace for the purified 67 Ga-labeled NOTA Z00477 (SEQ. ID No. 3)-NOTA polypeptide.
• FIG. 23 is an analytical HPLC of formulated 2 [top: UV channel at 280 nm showing ascorbate, 0.5 min and peptide precursor 3, 4.5 min; bottom: radioactivity channel showing 2, 5.1 min (RCP 95%) and a decomposition product at 4.6 min. [0042]
• FIG. 24 is a FASTlab 1M cassette layout for the preparation of 2 using tC2 SepPak purification.
• FIG. 25 is an analytical HPLC of formulated 2 prepared using FASTlabTM [top: radioactivity channel, showing 2 (7.7 min), 18 F-FBA (10.4 min) and an unknown impurity (12.2 min); middle: UV channel at 280 nm showing p-aminobenzoic acid formulation additive (3 min); bottom: UV channel at 350 nm showing dimethylaminobenzaldehyde by-product (10.2 min) and an unknown impurity (3.8 min)].
• FIG. 26 is a FASTlabTM cassette layout for the preparation of 2 using Sephadex purification.
• FIG. 27 is an analytical HPLC of formulated 2 prepared using FASTlab with Sephadex purification [top: radioactivity channel, showing 2 (7.1 min), 18 F-FBA (8.8 min) and an unknown impurity (10.2 min); middle: UV channel at 280 nm; bottom: UV channel at 350 nm showing dimethylaminobenzaldehyde by-product (10.0 min)].
• FIG. 28 is an analytical HPLC of formulated 5 [top: radioactivity channel, showing the product (4.7 min, 92 ) and a by-product (3.9 min, 8 ); bottom: UV channel at 280 nm].
• FIG. 29 depicts a time course study of 5 showing labelling efficiencies as measured by analytical radio HPLC.
• FIG. 30 is an analytical RCY of 5 after increasing the peptide/AlCl 3 concentration (P: product, BP: by-product, see Fig. FIG 28).
• FIG. 31 is an analytical HPLC profile of a labelling mixture of 5. (Top trace: radioactivity channel, bottom trace: UV channel at 280 nm).
• FIG. 32 is an analytical radioactivity channel HPLC of isolated 7 (Red: radioactivity channel, blue: UV channel at 280 nm).
• FIG. 33 depicts HER2 protein expression in tumour sections from the NCI- N87 and A431 xenograft models by immunohistochemistry the HERCEPTEST by DAKO. Pictures on the left are x2 magnification, pictures on the right are xlO of the highlighted square.
• FIG. 34 shows naive mice biodistributions of 9, 2, 5, and 7.
• FIG. 35 shows biodistributions of 9, 2, 5, and 7 in the NC87/A431 tumour bearing mice.
• FIG. 36 shows biodistribution profile of 2 in the dual tumour xenograft model.
• FIG. 37 shows NCI-N87 xenograft biodistribution profile of 2 using increasing concentrations of cold precursor.
• FIG. 38 shows preliminary imaging with 2 in the dual tumour xenograft model (A) and comparison to Affibody® 9 imaging study (B).
• the imaging agent compositions of the invention generally comprise an isolated polypeptide of SEQ. ID No. 1, SEQ. ID No. 2 or a conservative variant thereof, conjugated with a radioisotope such as, for example, 18 F, 99m Tc, 67 Ga or 68 Ga, m In, 123 I, 124 I, 89 Zr, or ⁇ Cu; and methods for making and using the compositions.
• the isolated polypeptide binds specifically to HER2 or its variant thereof.
• the sequence of the isolated polypeptide has at least 90% sequence similarity to any of SEQ. ID No. 1, SEQ. ID No. 2 or conservative variant thereof.
• the isolated polypeptide may comprise natural amino acids, synthetic amino acids, or amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
• Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, for example, hydroxyproline, ⁇ -carboxyglutamate, O-phosphoserine, phosphothreonine, and phosphotyrosine.
• the isolated polypeptides may be prepared using standard solid phase synthesis techniques. Alternatively, the polypeptides may be prepared using recombinant techniques. When the polypeptides are prepared using recombinant techniques, the DNA encoding the polypeptides or conservative variants thereof may be isolated. The DNA encoding the polypeptides or conservative variants thereof may be inserted into a cloning vector, introduced into a host cell (e.g., a eukaryotic cell, a plant cell, or a prokaryotic cell), and expressed using any art recognized expression system. [0060] The polypeptide may be substantially comprised of a single chiral form of amino acid residues. Thus, polypeptides of the invention may be substantially comprised of either L-amino acids or D-amino acids; although a combination of L- amino acids and D-amino acids may also be employed.
• residues on the binding interface may be non-conservatively substituted or conservatively substituted while preserving binding activity.
• the substituted residues may be derived from any of the 20 naturally occurring amino acids or any analog thereof.
• polypeptides may be about 49 residues to about 130 residues in length.
• the specific polypeptide sequences are listed in Table 1.
• Additional sequences may be added to the termini to impart selected functionality.
• additional sequences may be appended to one or both termini to facilitate purification or isolation of the polypeptide, alone or coupled to a binding target (e.g., by appending a His tag to the polypeptide).
• polypeptides listed in Table 1 may be conjugated with F via a linker; 99m Tc via a diaminedioxime chelator, with 67 Ga or 68 Ga via a NOTA chelator, with 18 F via an Al 1 l 8 o F-N0TA- chelator, with 1 1 8 0 F via SiFA (i.e., silicon fluoride acceptor) or silicon fluoride exchange chemistry, with ni In via DOTA chelator chemistry, with
• the isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID No. 2 or a conservative variant thereof, may be conjugated with 18 F.
• the 18 F may be incorporated at a C terminus, at a N-terminus, or at an internal position of the isolated polypeptide.
• the 18 F may be conjugated to the isolated polypeptide via a linker.
• the linker may comprise, an aminoxy group, an azido group, or an alkyne group.
• the aminoxy group of the linker may be attached with an aldehyde, such as a fluorine-substituted aldehyde.
• An azide group of the linker may be attached with a fluorine substituted alkyne.
• an alkyne group of the linker may be attached with a fluorine substituted azide.
• the linker may also comprise a thiol reactive group.
• the linker may comprise of a maleimido-aminoxy, maleimido- alkyne or maleimido- azide group.
• the 18 F conjugated polypeptide may be prepared by: (i) providing the isolated polypeptide comprising SEQ.ID No. 1, SEQ.ID No. 2, or a conservative variant thereof; (ii) reacting the polypeptide with a linker, wherein the linker comprises an aminoxy group, an azido group, or an alkyne group, to form a linker conjugated polypeptide; and reacting the linker with an 18 F moiety to form the 18 F conjugated polypeptide.
• the 18 F conjugated polypeptide may be prepared by: (i) providing the isolated polypeptide comprising SEQ.ID No. 1, SEQ.ID No. 2, or a conservative variant thereof; (ii) reacting the polypeptide with a linker, wherein the linker comprises a maleimido-aminoxy, maleimido-alkyne or maleimido-azide group, to form a linker
• the method may comprise: (i) providing an isolated polypeptide comprising SEQ. ID No. 1, SEQ. ID No. 2, or a conservative variant
• fluorine or radiofluorine atom(s), such as 18 F may be introduced onto the polypeptides.
• a fluorine-substituted polypeptide results when a fluorine-substituted aldehyde is reacted with the aminoxy group of the linker conjugated polypeptide.
• a fluorine substituted polypeptide results, when a fluorine substituted azide or alkyne group is reacted with the respective alkyne or azide group of the linker conjugated polypeptide.
• a radiofluorine-labeled polypeptide or imaging agent composition results, when a radiofluorine-substituted aldehyde, azide or alkyne is reacted with the respective aminoxy, alkyne or azide group of the linker conjugated polypeptide.
• the linker may have a
• radiofluorine ( F) substituent to prepare radiofluorine-labeled imaging agent compositions.
• the methods for introducing fluorine onto the polypeptide may also be used to prepare a fluorinated imaging agent composition of any length.
• the polypeptide of the imaging agent composition may comprise, for example, 40 to 130 amino acid residues.
• a linker-conjugated polypeptide or the 18 F-conjugated linker for use in the preparation of an imaging agent or imaging agent composition of the invention may be prepared by a method of the invention that is more efficient than previously known methods and result in higher yields.
• the methods are easier to carry out, faster and are performed under milder, more user friendly, conditions. For example, the method
• F-conjugated linker e.g., F-
• F-FBA 18 18 fluorobenzaldehydeX
• F-FBA is simpler than the procedures known in the art.
• F conjugated-linker is prepared in one step by the direct nucleophilic incorporation of F onto the trimethylanilinium precursor.
• F-linker i.e., F-FBA
• F-FBA is then conjugated to the polypeptide, such as, for example, an Affibody® and those described herein.
• the preparation of the linker is also easier than previously known methods in the art.
• radiolabeled aminoxy based linker-conjugated polypeptides and the cPn family of chelator conjugated polypeptides (e.g., Affibody®), show significantly better biodistribution and better tumor uptake, as well as better clearance with less liver uptake.
• the fluorine-labeled imaging agent compositions are highly desired materials in diagnostic applications. 18 F labeled imaging agent compositions may be visualized using established imaging techniques such as PET.
• the polypeptide may be conjugated with 99m Tc via a diamindioxime chelator of formula (1).
• R , R", R'", R" is independently H or C 1-10 alkyl, C 3 _i 0 alkylary, C 2-10 alkoxyalkyl, C MO hydroxyalkyl, C MO alkylamine, C MO fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached to form a carbocyclic, heterocyclic, saturated or unsaturated ring, wherein R may be H, C MO alkyl, C 3-10 alkylary, C 2-10 alkoxyalkyl, C MO hydroxyalkyl, C MO alkylamine, or C MO fluoroalkyl.
• n may vary from 0-5.
• the 99m Tc may be conjugated to the isolated polypeptide via the diamindioxime at the N-terminus of the isolated polypeptide.
• the chelator may be a bifunctional compound.
• the bifunctional compound may be Mal- cPN216.
• the Mal-cPN216 comprises a thiol-reactive maleimide group for conjugation to a terminal cysteine of the polypeptide of SEQ ID No. 1 or SEQ ID No 2 and a bis-amineoxime group (diamindioxime chelator) for chelating with 99m Tc.
• the Mal-cPN216 may have a formula (II).
• the diamindioxime chelator conjugated peptide may be prepared by (i) providing an isolated polypeptide comprising SEQ.ID No. 1, SEQ. ID No. 2 or a conservative variant thereof, (ii) reacting a diamindioxime chelator with the polypeptide to form the diamindioxime conjugated polypeptide.
• the diamindioxime chelator may be further conjugated with 99m Tc.
• the polypeptide may be conjugated with 67 Ga, or 68 Ga via NOTA (l ,4,7-triazacyclononane-N,N',N"-triacetic acid) chelator.
• the NOTA-chelator conjugated polypeptide may be prepared by (i) providing an isolated polypeptide comprising SEQ.ID No. 1, SEQ. ID No. 2 or a conservative variant thereof, (ii) reacting a NOTA chelator with the polypeptide to form the NOTA- chelator conjugated polypeptide.
• the NOTA chelator may be further conjugated with
• the Ga may be conjugated to the isolated polypeptide via NOTA chelator.
• the NOTA chelator may be functionalized with a maleimido group, as described in formula (III).
• the polypeptide may be conjugated with Al F via NOTA (l ,4,7-triazacyclononane-N,N',N"-triacetic acid) chelator
• the NOTA- conjugated polypeptide may be prepared by (i) providing an isolated polypeptide comprising SEQ.ID No. 1, SEQ. ID No. 2 or a conservative variant thereof, (ii) reacting a NOTA- chelator with the polypeptide to form the NOTA- chelator conjugated polypeptide.
• the NOTA- chelator conjugated polypeptide may then be
• the polypeptide may be conjugated with 18 F via NOTA- chelator.
• the NOTA- chelator conjugated polypeptide may be prepared by (i) providing an isolated polypeptide comprising SEQ.ID No. 1 , SEQ. ID No. 2 or a conservative variant thereof, (ii) reacting a NOTA- chelator with a source of 18 F (e.g., A1 18 F) to form an 18 F-NOTA- chelator; and (iii) reacting the 18 F-NOTA- chelator with a source of 18 F (e.g., A1 18 F) to form an 18 F-NOTA- chelator; and (iii) reacting the 18 F-NOTA- chelator with
• a chelator may comprise a chelate moiety (e.g. NOTA, DOTA) alone or a chelate moiety and a linker, each as described herein.
• a NOTA-chelator can represent a NOTA chelate moiety alone or a NOTA chelate moiety attached to a linker as described herein.
• the polypeptide may be conjugated with 18 F via
• the F-SiFA conjugated polypeptide may be prepared by: (i) providing the isolated polypeptide comprising SEQ.ID No. 1, SEQ.ID No. 2, or a conservative variant thereof; (ii) reacting the polypeptide with a linker, wherein the linker comprises a silicon fluoride acceptor (SiFA) group, to form a SiFA conjugated
• 18 polypeptide and (iii) reacting the SiFA conjugated polypeptide with an F moiety or a source of 18 F.
• the 18 F moiety or source of 18 F can any such moiety or source capable of reacting with a SiFA group and undergo isotopic fluorine exchange chemistry.
• Scheme I below illustrates radiolabelling of Z02891 (SEQ. ID No. 2) using [ 18 F]SiF coupling:
• a radiolabeled imaging agent or imaging agent composition of the invention may be conveniently prepared in an automated fashion by means of an automated radiosynthesis apparatus.
• an automated radiosynthesis apparatus There are several commercially-available examples of such platform apparatus, including TRACERlabTM (e.g., TRACERlabTM MX) and FASTlabTM (both from GE Healthcare Ltd.).
• TRACERlabTM e.g., TRACERlabTM MX
• FASTlabTM both from GE Healthcare Ltd.
• Such apparatus commonly comprises a "cassette", often disposable, in which the radiochemistry is performed, which is fitted to the apparatus in order to perform a radiosynthesis.
• the cassette normally includes fluid pathways, a reaction vessel, and ports for receiving reagent vials as well as any solid-phase extraction cartridges used in post-radiosynthetic clean up steps.
• the automated radiosynthesis apparatus can be linked to a high performance liquid chromatograph (HPLC).
• HPLC high performance liquid chromatograph
• the present invention therefore provides a cassette for the automated synthesis of a radiolabeled imaging agent or imaging agent composition of the invention, each as defined herein.
• the invention also comprises methods of imaging at least a portion of a subject.
• the method comprises administering a radiolabeled imaging agent or an imaging agent composition of the invention to a subject and imaging the subject.
• the subject may be imaged, for example, with a diagnostic device.
• a method of imaging may further comprise the steps of monitoring the delivery of the agent or composition to the subject and diagnosing the subject with a HER2-associated disease condition (e.g., breast cancer).
• the subject may be a mammal, for example, a human.
• the subject may comprise cells or tissues. The tissues may be used in biopsy.
• the diagnostic device may employ an imaging method chosen from magnetic resonance imaging, optical imaging, optical coherence tomography, X-ray, single photon emission computed tomography (SPECT), positron emission tomography (PET), or combinations thereof.
• a radiolabeled imaging agent or an imaging agent composition of the invention may be administered to humans and other animals parenterally as a pharmaceutical composition.
• a pharmaceutical composition of the invention comprises a radiolabeled imaging agent or an imaging agent composition, as described herein, and a pharmaceutically acceptable carrier, excipient, solvent or diluent.
• a pharmaceutical composition of this invention for parenteral injection comprise pharmaceutically-acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
• suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
• Proper fluidity can be maintained, for example, by using coating materials such as lecithin, by adjusting the particle size in dispersions, and by using surfactants.
• a pharmaceutical composition of the invention may also contain an adjuvant such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents, which delay absorption such as aluminum monostearate and gelatin.
• a radiolabeled imaging agent or an imaging agent composition of the invention may be dispersed in physiologically acceptable carrier to minimize potential toxicity.
• the imaging agents may be dispersed in a biocompatible solution with a pH of about 6 to about 8.
• the agent is dispersed in a biocompatible solution with a pH of about 7 to about 7.4.
• the agent is dispersed in a biocompatible solution with a pH of about 7.4.
• An imaging agent composition or a pharmaceutical composition of the invention may be combined with other additives that are commonly used in the pharmaceutical industry to suspend or dissolve the compounds in an aqueous medium, and then the suspension or solution may be sterilized by techniques known in the art.
• the imaging agent composition may be administered in a variety of forms and adapted to the chosen route of administration.
• the agents may be administered topically (i.e., via tissue or mucus membranes), intravenously, intramuscularly, intradermally, or subcutaneously.
• Forms suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the preparation of sterile injectable solutions, dispersions, liposomal, or emulsion formulations.
• Forms suitable for inhalation use include agents such as those dispersed in an aerosol.
• Forms suitable for topical administration include creams, lotions, ointments, and the like.
• An imaging agent composition or a pharmaceutical composition of the invention may be concentrated to conveniently deliver a preferred amount of the agents to a subject and packaged in a container in the desired form.
• the agent may be dispensed in a container in which it is dispersed in a physiologically acceptable solution that conveniently facilitates administering the agent in concentrations between 0.1 mg and 50 mg of the agent per kg body weight of the subject.
• the target tissue may be imaged about four hours after administering the agents. In alternative embodiments, the target tissue may be imaged about 24 hours after administering the agents to the subject.
• a panel of tumorigenic cell lines with a reasonable probability of expressing HER2 was selected based on available literature (Bruskin, et. al. Nucl. Med. Biol. 2004: 31 : 205; Tran, et. al. Imaging agent composition Chem. 2007: 18: 1956), as described in Table3.
• Adherent cells were released from their flasks using cell dissociation buffer (PBS + 10 mM EDTA) rather than trypsin to avoid proteolysis of cell surface receptors.
• Cells were washed twice in PBS and resuspended in ice-cold FC buffer (PBS + 0.5 % BSA w/v) to a concentration of 5-10 x 106 cells/ml. 100 ⁇ . aliquots of cells were mixed with 5 ⁇ g of primary antibody and incubated, on ice, for 45 minutes.
• FC ice cold flow cytometry
• PBS 2% bovine serum albumin
• F(ab) 2 FITC -conjugated goat anti-mouse Immunoglobulins was added and incubated, on ice and in the dark, for 45 minutes.
• Cells were then washed twice with 1 mL of ice cold FC buffer, centrifuged at 300 x g for 5min, and resuspended in 500 ⁇ L ⁇ of FC buffer. All stained cells were passed through a 100-micron filter prior to flow cytometry to prevent clogs of the flow cell.
• Flow cytometry was carried out on a Beckman Coulter Cytomics FC500 MPL. A minimum of 5 x 10 4 events was collected for each tube. All analyses were single color, with detection of FITC in FL1. Forward scatter (FS) and side scatter (SS) data demonstrated that all cell populations were tightly grouped.
• FS Forward scatter
• SS side scatter
• the highest expressing cell line was SKOV3. These cells were injected into 6-12 week old immuno-compromised mice and allowed to grow tumors. Tumor growth curves and success rates were dependent on the number of cells inoculated. Optimal tumor growth was obtained with three to four million cells/mouse
• mice Male CD-I nude mice (Charles River Labs, Hopkinton, MA) with an age range between 6 and 15 weeks. Mice were housed in a ventilated rack with food and water ad libitum and a standard 12 hour day-night lighting cycle. For xenografts, animals were injected with 100 ⁇ of cells in PBS. Cells were implanted subcutaneously in the right hindquarter. Implantation was performed under isoflurane anesthesia. For SKOV3, between 3 x 10 6 to 4 x 10 6 cells were implanted in each mouse. Under these conditions, useable tumors (100 to 300 ⁇ g) were obtained in 3 to 4 weeks in greater than 80% of animals injected.
• Tumors were collected from mice by dissection, and whole tumors were stored at -20°C until processing. Tumors were ground on ice in 1 ml of RIPA buffer supplemented with a protease inhibitor cocktail (Santa Cruz Biotech, Santa Cruz, CA #24948) in a Dounce homogenizer. Homogenates were then incubated on ice for 30 minutes, then centrifuged at 10,000 x G for 10 minutes in a refrigerated centrifuge. Supernatants were collected and stored on ice or at 4°C until further processing. Protein concentrations in lysates were determined using a BCA protein assay kit (Pierce Biotechnology 23225).
• Lysates were diluted to a standard concentration to yield 20 ⁇ g of protein/well in the microtiter plate.
• ELISA's were run with a commercially available human HER2 kit (R&D Systems, DYC1129) according to the manufacturer's instructions. Each sample was run in triplicate, and data are reported as pg HER2 ⁇ g total protein, errors are reported as standard deviations.
• Target expression in vivo was measured by ELISA.
• Excised tumors were homogenized and analyzed for HER2 using a commercially available matched pair kit (R&D systems, DYC1129, Minneapolis, MN). The results, in FIG. 3, show that the SKOV3 cell line grows a high-expressing tumor.
• ELISA controls were cell-culture lysates of the negative control lines used for flow cytometry. These results indicate that tumor xenografts of SKOV3 are appropriate for the in vivo study of molecules targeting human HER2.
• polypeptides were received from Affibody® AB in Sweden.
• the polypeptides are referred to by their numeric internal development codes, which are prefixed with "Z".
• Table 1 details the polypeptides described herein.
• the polypeptides include polypeptide Z00342 (SEQ. ID No. 1); polypeptide Z02891 (SEQ. ID No. 2); polypeptide Z00477 (SEQ. ID No. 3 and 4), and dimer of Z00477, i.e., (Z00477) 2 (SEQ. ID No. 5).
• Binding interactions between the polypeptids and the HER2/neu antigen were measured in vitro using surface plasmon resonance (SPR) detection on a BiacoreTM 3000 instrument (GE Healthcare, Piscataway, NJ).
• SPR surface plasmon resonance
• the extracellular domain of the Her2/neu antigen was obtained as a conjugate with the Fc region of human IgG (Fc-Her2) from R&D Systems (Minneapolis, MN) and covalently attached to a CM-5 dextran-functionalized sensor chip (GE Healthcare, Piscataway, NJ) pre-equilibrated with HBS-EP buffer (0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% v/v surfactant P20) at 10 ⁇ /min and subsequently activated with EDC and NHS.
• HBS-EP buffer 0.01M HEPES pH 7.4, 0.15M NaCl, 3mM EDTA, 0.005% v/v surfactant P20
• the Fc-HER2 (5 ⁇ g/ml) in 10 mM sodium acetate (pH 5.5) was injected onto the activated sensor chip until the desired immobilization level (-3000 Resonance Units) was achieved (2 min). Residual activated groups on the sensor chip were blocked by injection of ethanolamine (1 M, pH 8.5). Any non-covalently bound conjugate was removed by repeated (5x) washing with 2.5 M NaCl, 50 mM NaOH. A second flow cell on the same sensor chip was treated identically, except with no Fc- HER2 immobilization, in order to serve as a control surface for refractive index changes and non-specific binding interactions with the sensor chip.
• FIG. 1 shows example surface plasmon resonance (SPR) data obtained for Z00477 (SEQ. ID No. 3) and (Z00477) 2 (SEQ. ID No. 5) when run on human HER2- functionalized surfaces. This relationship holds true for all polypeptides for which the affinities are known (Table 2), in which the values for the dimer Z(477)2 (SEQ. ID No. 5) are estimates based on avidity affect.
• SPR surface plasmon resonance
• the resulting solution was heated to 95 °C for 15-20 minutes, to give fac-[ 99m Tc(CO) 3 (H 2 0)3] + .
• a portion (2 mCi, 1 mL) of the solution was removed and neutralized to pH ⁇ 7 with 1 N HC1.
• a 325 ⁇ L ⁇ aliquot was removed and added to a solution of the His6-Polypeptide (SEQ ID NO: 7) (40 ⁇ g).
• the resulting solution was heated in a water bath at 35-37°C for 40 minutes.
• Typical radiochemical yields ranged from 80-95% (determined by ITLC- SG, Biodex, 0.9% NaCl).
• the crude reaction products were chromatographed on a NAP-5 column (GE Healthcare, 10 mM PBS) to give products of >99% radiochemical purity. Typical specific activities obtained were 3-4 ⁇ Ci/ ⁇ g.
• the resulting solution was then diluted with 10 mM PBS to give the proper concentration for subsequent biodistribution studies.
• HPLC was carried out on an Agilent 1100 series HPLC equipped with a Grace- Vydac Peptide/Protein C4 (4.6 x 250 mm) column and a Raytest GABI radioactivity detector.
• Solvent A was 95:5 watenMeCN with 0.1% TFA
• solvent B was 5:95 watenMeCN with 0.1% TFA.
• the gradient was as follows (all changes linear; time/%B): 0/0, 4/20, 16/60, 20/100, 25/100, 26/0, 31/0.
• FIG. 4 Representative HPLC chromatograms of NAP-5 purified radiolabeled polypeptides are shown in FIG. 4. The retention time of the radiolabeled species was virtually unchanged from the corresponding unlabeled polypeptide's retention time in a 220 nm UV chromatogram (except for the time difference due to the physical separation of the UV and gamma detectors; data not shown).
• mice Male CD-I nude mice (Charles River Labs, Hopkinton, MA) with an age range between 6 and 15 weeks. Mice were housed in a ventilated rack with food and water ad libitum and a standard 12 hour day-night lighting cycle. For xenografts, animals were injected with 100 ⁇ of cells in PBS. Cells were implanted subcutaneously in the right hindquarter. Implantation was performed under isoflurane anesthesia. For SKOV3, between 3 x 10 6 to 4 x 10 6 cells were implanted in each mouse. Under these conditions, useable tumors (100 to 300 ⁇ g) were obtained in 3 to 4 weeks in greater than 80% of animals injected.
• xenografts animals were injected with 100 ⁇ of cells in PBS. Cells were implanted subcutaneously in the right hindquarter. Implantation was performed under isoflurane anesthesia. For SKOV3, between 3 x 10 6 to 4 x 10 6 cells were implanted in each mouse
• mice were given tail-vein injections of ⁇ 1 ⁇ g of 99m Tc-labeled polypeptides ( ⁇ 3 ⁇ /l ⁇ g). Mice were placed in filter-paper lined cages until euthanasia. Three mice were euthanized at each timepoint and tissues of interest dissected and counted on a Perkin Elmer Wallac Wizard 1480 Gamma Counter. Data were collected for blood, kidney, liver, spleen, and injection site (tail). Urine from cages was pooled with the bladder and also counted. The remaining tissues were counted and the sum of all tissues plus urine for each animal was summed to provide the total injected dose.
• % injected dose for each organ was determined based on this total, and organs were weighed for determination of the % injected dose per gram, (%ID/g). Data is reported as mean value for all three mice in the timepoint with error bars representing the standard deviation of the group.
• the 99m Tc labeled Z00477 (SEQ. ID No. 4) polypeptide was injected into SKOV3 mice.
• FIG. 6 shows the tumor and blood curves for these experiments.
• the Z00477 (SEQ. ID No. 4) polypeptide shows good tumor uptake in target-expressing SKOV3 tumors, with a maximal value of approximately 3% of the injected dose per gram of tissue at 30 minutes post- injection (PI), and a peak tumor: blood ratio of more than 8 at 240 minutes PI.
• Polypeptides exhibit a monoexponential clearance from the blood with half-lives of less than two minutes. This clearance is primarily mediated by the liver and kidneys. Polypeptide uptake in the spleen was moderate, and moderate to high uptake in the liver is observed, as described in Table 5.
• Bivalent polypeptides exhibit higher affinity than the corresponding monomers, presumably due to the avidity effect. Their larger size, however, may hinder tumor penetration.
• HER2 polypeptides bivalent forms of each the four high affinity polypeptides were available.
• the monovalent and bivalent polypeptides otherwise exhibit similar biodistribution characteristics, and blood half-lives are observed for both in the one to two minute range. The results clearly indicate that both monomeric and divalent polypeptides can be targeted to HER2 in vivo.
• cPN216-amine was obtained from GE Healthcare.
• ⁇ - ⁇ - maleimidopropionic acid was purchased from Pierce Technologies (Rockford, IL).
• N- methylmorpholine, (benzotriazol- 1 -yloxy) tripyrrolidinophosphonium hexafluorophosphate (PyBoP), dithiothreitol (DTT), ammonium bicarbonate, and anhydrous DMF were purchased from Aldrich (Milwaukee, WI).
• PBS buffer (lx, pH 7.4) was obtained from Invitrogen (Carlsbad, CA).
• HPLC-grade acetonitrile (CH 3 CN), HPLC-grade trifluoroacetic acid (TFA), and Millipore 18 ⁇ water were used for HPLC purifications.
• the polypeptide Z00477 (SEQ ID No. 3) was dissolved with freshly degassed PBS buffer (lx, pH 7.4) at a concentration of approximately 1 mg/mL.
• the disulfide linkage in the polypeptide was reduced by the addition of DTT solution in freshly degassed PBS buffer (lx, pH 7.4).
• the final concentration of DTT was 20 mM.
• the reaction mixture was vortexed for 2 hours and passed through a Zeba desalt spin column (Pierce Technologies) pre-equilibrated with degassed PBS buffer (lx, pH 7.4) to remove excess of DTT reagent.
• the eluted reduced polypeptide molecule was collected, and the bifunctional compound Mal-cPN216 was added (20 equivalents per equivalent of the polypeptide) as a solution in DMSO, and the mixture was vortexed at room temperature for 3 hours and frozen with liquid-nitrogen. The reaction mixture was stored overnight before being subject to Reverse phase HPLC purification (FIGs. 8 A and 8B).
• LC-MS analysis of the purified product confirmed the presence of the desired product, and the MW suggested that only one cPN216 label was added to polypeptide constructs (Z00477 (SEQ. ID No. 3)-cPN216: calculated MW: 7429 Da, found: 7429 Da; Z02891 (SEQ. ID No. 2) -cPN216 calculated MW: 7524 Da, found: 7524 Da).
• Tin chloride 1.6 mg, 7.09xl0 "6 mol
• MDP 2.5 mg, 1.42xl0 "5 mol
• 10 aliquots were removed and transferred under a stream of nitrogen to silanized vials, immediately frozen and maintained in a liquid nitrogen bath until lyophilization.
• Each vial was partially capped with rubber septa and placed in a tray lyophilizer overnight. Vials were sealed under vacuum, removed from the lyophilizer, crimp-sealed with aluminum caps, re- pressurized with anhydrous nitrogen and stored in a freezer until future use.
• C4 RP-HPLC method 2 Solvent A: 0.06% NH 3 in water, Solvent B: CH 3 CN. Gradient elution: 0 min. 0%B, 4 min. 20%B, 16min. 60%B, 20 min. 100%B, 25 min. 100%B, 26 min. 0%B, 31 min. 0%B.
• SEC HPLC Solvent: lx (10 mM) PBS (Gibco, Invitrogen, pH 7.4 containing CaCl 2 and MgCl 2 ). Isocratic elution for 30 min. Analysis performed on a: Perkin Elmer SEC-4 Solvent Environmental control, Series 410 LC pump, ISS 200 Advanced LC sample processor and Series 200 Diode Array Detector. A Raytest GABI with Socket 8103 0111 pinhole (0.7 mm inner diameter with 250 ⁇ L ⁇ volume) flow cell gamma detector was interfaced through a Perkin Elmer NCI 900 Network Chromatography Interface. The column used was a Superdex 75 10/300 GL High Performance SEC column (GE Healthcare, code: 17-5174-01, ID no. 0639059).
• mice were given tail-vein injections of ⁇ 1 ug of 99m Tc-labeled polypeptides (-10 ⁇ ⁇ g). Mice were placed in filter-paper lined cages until euthanasia. Three mice were euthanized at each timepoint and tissues of interest dissected and counted on a Perkin Elmer Wallac Wizard 1480 Gamma Counter. Data were collected for blood, kidney, liver, spleen, and injection site (tail). Urine from cages was pooled with the bladder and also counted. The remaining tissues were counted and the sum of all tissues plus urine for each animal was summed to provide the total injected dose.
• % injected dose for each organ was determined based on this total, and organs were weighed for determination of the % injected dose per gram, (%ID/g). Data is reported as mean value for all four to five mice in the time point with error bars representing the standard deviation of the group. Four time points were taken over four hours (5, 30,120, and 240 minutes post-injection).
• Tumor blood ratios were 2, 5, and 5 at 30, 120, and 240 min post injection, respectively.
• FIG. 10, 11 and 12 show the tumor, blood and tumor: blood curves for these experiments.
• Z00477 SEQ. ID. NO. 4
• Z00342 SEQ. ID No. 1
• Z02891 SEQ. ID No. 2-cysteine polypeptides were functionalized with an aminoxy group via an engineered C-terminal cysteine.
• the purity of the polypeptide molecules provided was determined to be >95% by High Performance Liquid Chromatography (HPLC).
• a bifunctional linker Mal-aminooxy was synthesized comprising of two orthogonal groups: a thiol-reactive maleimide group for conjugation to the engineered cysteine and an aldehyde-reactive aminoxy group (FIGs. 13 A and 13B).
• This linker was prepared by reacting N-(2- aminoethyl) malemide with 2-(tert-butoxycarbonylaminooxy) acetic acid using 1- ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC) -mediated coupling conditions yielding the Boc-protected form of the linker.
• EDC 1- ethyl-3-[3-dimethylaminopropyl] carbodiimide
• the polypeptide (Z00477(SEQ ID No. 4), Z00342 (SEQ ID No. 1) Z02891 (SEQ ID. No. 2)) was dissolved with freshly degassed PBS buffer (lx, 7.4) at a concentration of approximately 1 mg/mL.
• the disulfide linkage in the polypeptide was reduced by the addition of dithiothreitol (DTT) solution in freshly degassed PBS buffer (lx, pH 7.4).
• the final concentration of DTT is 20 mM.
• the reaction mixture was vortexed for 2 hours and eluted through a Zeba desalt spin column (Pierce Technologies) pre-equilibrated with degassed PBS buffer to remove excess of DTT reagent.
• the reduced polypeptide was collected, and the bifunctional Mai- AO compound was added (15 equivalents per equivalent of the polypeptide) as a solution in DMSO. After being vortexed at room temperature overnight, the reaction mixture was purified with High Performance Liquid Chromatography (HPLC) (FIGs. 14A and 14B).
• HPLC High Performance Liquid Chromatography
• ESI-TOF-MS analysis confirmed the presence of target product with the expected molecular weights (calculated MW: 6964 Da, 8531 Da, and 7243 Da, found: 6963 Da, 8532 Da, and 7244 Da for Z00477 (SEQ. ID No. 4)-ONH 2 , Z00342 (SEQ. ID No. l)-ONH 2 , and Z02891 (SEQ. ID No. 2) -ONH 2 , respectively.
• K 18 F (40mCi mL 1 (1480 MBq mL "1 ) in purified water) was obtained from IBA Molecular (Albany, NY) and PETNET Solutions (Albany, NY) and were used as received.
• the [ 18 F ⁇ ] fluoride was first immobilized on a Chromafix 30-PS-HCO3 anion exchange cartridge (ABX, Radeberg, Germany), then eluted into a drydown vessel with a 1 mL, 4:1 mixture of acetonitrile: distilled, deionized H 2 0 (ddH 2 0) containing Kryptofix K222 (376 g.mol 1 , 8 mg, 2.13xl0 ⁇ 5 mol) and potassium carbonate (138.2 g.mol "1 , 2.1 mg, 1.52xl0 ⁇ 5 mol).
• the solvent was removed under partial vacuum and a flow of nitrogen with gentle heating ( ⁇ 45°C) (-15 min).
• the source vial and anion exchange cartridge were then washed with 0.5mL of acetonitrile containing K222 (8 mg) and the reaction mixture again brought to dryness under partial vacuum and gentle heating (- 10 min).
• the reaction vessel was repressurized with nitrogen and the azeotropic drydown repeated once with an additional 0.5mL of acetonitrile.
• the vessel was capped, crimped, placed in a heating block and maintained at 60°C for 15 minutes; at which point a small aliquot ( ⁇ 5 ⁇ ) was removed for analytical HPLC analysis .
• 450 ⁇ L ⁇ of ddH 2 0 with 0.1% TFA was used to dilute the solution to approx. 500 ⁇ L ⁇ in preparation for semi-preparative HPLC purification.
• 18 FB-Polypeptide was isolated and purified by semi-preparative HPLC .
• the HPLC fraction containing the product (0.113 mCi/4.18MBq) was diluted 5:1 with ddH 2 0 and subsequently immobilized on a tC18 Plus Sep Pak (Waters).
• 18 F-labeled polypeptides were isolated by NAP5 size exclusion chromatography by diluting the reaction mixture to approximately 0.5mL with lOmM PBS and loading onto the gel.
• the 18 F-labled polypeptides were isolated by eluting the column with 0.8 mL of lOmM PBS and used without further modification. These results are illustrated in Table 8, and FIG. 15.
• Analytical HPLC conditions used are as follows: Analysis performed on an HP Agilent 1100 with a G1311A QuatPump, G1313A autoinjector with ⁇ syringe and 2.0mL seat capillary, Phenomenex Gemini CI 8 column (4.6mmxl50mm), 5 ⁇ , 100A (S/N 420477-10), G1316A column heater, G1315A DAD and Ramon Star - GABI gamma-detector. 95:5 ddH 2 0:CH 3 CN with 0.05% TFA, Solvent B: CH 3 CN with 0.05% TFA. Gradient elution (1.0 mL min 1 ): 0 min. 0%B, 1 min.
• mice were given tail- vein injections of ⁇ 1 ug of 18 F-labeled polypeptide ( ⁇ 4 uCi/1 ⁇ g). Mice were placed in filter-paper lined cages until euthanasia. Three mice were euthanized at each timepoint and tissues of interest dissected and counted on a Perkin Elmer Wallac Wizard 1480 Gamma Counter. Data were collected for blood, kidney, liver, spleen, bone and injection site (tail). Urine from cages was pooled with the bladder and also counted. The remaining tissues were counted and the sum of all tissues plus urine for each animal was summed to provide the total injected dose.
• the percent injected dose for each organ was determined based on this total, and organs were weighed for determination of the percent injected dose per gram, (%ID/g). Data is reported as mean value for all three mice in the timepoint with error bars representing the standard deviation of the group.
• the polypeptides underwent biodistribution studies in SKOV3 cell xenograft models. Four time points were taken over four hours (5, 30, 120, and 240 minutes post-injection). Complete biodistribution data are included in Table 12 (%ID/g Z02891 (SEQ. ID No. 2) - 18 F-fluorobenzyl oxime in SKOV3 Tumor Bearing Mice) and table 13 (%ID/g Z00342 (SEQ. ID No. 1) 18 F-fluorobenzyl oxime in SKOV3 Tumor Bearing Mice).
• FIGs. 16, 17 and 18 show the tumor, blood, tumor: blood, and clearance curves for these tests.
• Tumor blood ratios were approximately 3, 34, and 128 at 30, 120, and 240 min post injection, respectively.
• Tumor blood ratios were approximately 3, 32 and 53 at 30, 120 and 240 min post injection, respectively.
• Polypeptide Z00477 (SEQ. ID 3) was labeled with Ga, specifically b/ Ga, after a NOTA (l,4,7-triazacyclononane-N,N',N"-triacetic acid) chelator was conjugated to the polypeptide. (Fig. 19)
• Bioconjugation of Mal-NOTA to polypeptide molecules was accomplished as follows.
• the polypeptide was dissolved with freshly degassed PBS buffer (lx, pH 7.4) at a concentration of approximately 1 mg/mL.
• the disulfide linkage in the polypeptide was reduced by the addition of DTT solution in freshly degassed PBS buffer (lx, pH 7.4).
• the final concentration of DTT was 20 mM.
• the reaction mixture was vortexed for 2 hours and passed through a Zeba desalt spin column (Pierce Technologies) pre-equilibrated with degassed PBS buffer (lx, pH 7.4) to remove excess of DTT reagent.
• the eluted reduced polypeptide molecule was collected, and the bifunctional compound mal-NOTA was added (15 equivalents per equivalent of the polypeptide) as a solution in DMSO, and the mixture was vortexed at room temperature. The reaction was allowed to proceed overnight to ensure the complete conversion of the polypeptide molecules.
• Reverse phase HPLC analysis of the crude reaction mixture determined the radiochemical purity of the 67 Ga-NOTA Z00477 (SEQ. ID No. 3) was determined to be 95% by HPLC after 2 hours at room temperature.
• Recombinant HER2 Z28921-Cys was purchased from Affibody AB, Sweden, Eei-aminooxyacetic acid succinic ester from IRIS Biotech, and di-tert- butyldifluorosilane was purchased from Fluorochem. Reagents and solvents were purchased from IRIS Biotech, Merck, Romil and Fluka.
• DIPEA Diisopropylethylamine
• DMAB 4-dimethylamino-benzaldehyde
• DOTA l ,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetic acid
• HER2 Human Epidermal growth factor receptor
• NMP 1 -Methyl-2-pyrrolidinone
• PET Positron emission tomography
• SiFA 4-(Di-tert-butylfluorosilyl)benzaldehyde
• TFA Trifluoroacetic acid
• TIS Triisopropylsilane
• [18F]Fluorobenzaldehyde (“[18FJFBA”) yielding typically 7 GBq of [18FJFBA in ethanol (1.5 mL, non-decay corrected yields 12-54%).
• a small fraction (92 ⁇ ) of this [18FJFBA solution was then manually conjugated to the aminoxy precursor 3 (0.4 mg, 55 nmol) in the presence of aniline hydrochloride (3.2 mg, 25 ⁇ ) in water (138 ⁇ ) in a silanised P6 vial.
• the mixture was heated at 70°C for 20 minutes using a Peltier heater. 2 was isolated via size exclusion chromatography (NAP5 cartridge, GE Healthcare).
• the product was further analysed by HPLC using a Gilson 322 pump with a Gilson UV/ViS 156 detector, a Bioscan Flow-Count radioactivity detector, and a Luna C18 Phenomenex column (50 x 4.6 mm, 3 ⁇ ) or a Luna C18 Phenomenex column (150 x 4.6 mm, 5 ⁇ ).
• the mobile phase comprised of solvents A (0.1 M ammonium acetate) and B (acetonitrile) running at 1 mL/min with a linear gradient (5-95 % B in 15 min).
• the UV absorbance was measured at 280 and 350 nm.
• FIG. 23 shows a representative example of an analytical HPLC trace of the formulation of 2.
• N-(2-Aminoethyl)maleimide TFA salt 51 mg, 0.20 mmol
• Eei-AOAc- OSu 77 mg, 0.30 mmol
• NMP 2 mL
• Sym.-collidine 80 ⁇ , 0.6 mmol
• the reaction mixture was diluted with water (7 mL) and the product, eei-aminooxyacetyl-maleimide, purified by semi -preparative HPLC.
• Recombinant Z02891-Cys (144 mg, 0.205 mmol)(purchased from Affibody AB, Sweden) and eei-aminooxyacetyl-maleimide (17 mg, 0.60 mmol) were dissolved in water (3 mL). The solution was adjusted to pH 6 by addition of ammonium acetate and the reaction mixture shaken for 90 min. The reaction mixture was diluted with water (7 mL) and the product purified by semi-prep HPLC affording 126 mg lyophilised Eei-protected product. The eei-protected product was treated with 2.5% TF A/water (16 mL) under a blanket of argon for 20 min.
• a FASTlabTM cassette was assembled containing a first vial (8.25 mg/21.9 ⁇ Kryptofix, 1.16 mg/8.4 ⁇ mol K2CO 3 , 165 ⁇ L ⁇ water, 660 ⁇ L ⁇ acetonitrile), a second vial (1.5 mg/4.8 ⁇ mol triflate 1, 1.5 mL anhydrous DMSO), a third vial (5.5 mg/0.76 ⁇ 3, 8.2 mg/63 ⁇ aniline hydrochloride, 0.7 mL ammonium acetate buffer pH 4.5/0.25 M), a fourth vial (4 mL, 4 % w/v aqueous ammonia), external vials of ethanol (25 mL) and phosphoric acid (1 % w/w, 25 mL), a pre-conditioned QMA light SepPak cartridge, an OASIS MCX SepPak cartridge, and two l C2 SepPak cartridges.
• the product vial contained an aqueous solution of p-amin
• the required programme sequence was uploaded from the PC control to the synthesizer module and the assembled cassette mounted onto the machine.
• a water bag and a product vial were attached.
• a vial containing [ 18 F]water (300 MBq, 1 mL) was attached to the FASTlabTM module and the radiosynthesis commenced.
• the process included an azeotropic drying step of the [ 18 F]-Kryptofix/potassium carbonate complex as eluted from the QMA cartridge, the radiosynthesis of [ 18 F]FBA, the purification of [ 18 F]FBA using the MCX cartridge, ammonia solution and elution with ethanol, the conjugation step to produce 2, and the purification and formulation step using phosphoric acid/ethanol on the l C2 cartridges.
• the total process took one hour and generated 2 in 33 % non-decay corrected radiochemical yield with 94 % radiochemical purity.
• a FASTlabTM cassette was assembled containing a first vial (8.25 mg/21.9 ⁇ Kryptofix, 1.16 mg/8.4 ⁇ K2CO 3 , 165 ⁇ L ⁇ water, 660 ⁇ L ⁇ acetonitrile), a second vial (1.5 mg/4.8 ⁇ triflate 1, 1.5 mL anhydrous DMSO), a third vial (5.0 mg/0.69 ⁇ 3, 8.2 mg/63 ⁇ aniline hydrochloride, 0.7 mL ammonium acetate buffer pH 4.5/0.25 M), a fourth vial (4 mL, 4 % w/v aqueous ammonia), external vials of ethanol (25 mL) and saline (Polyfusor, 0.9 % w/v, 25 mL), a pre-conditioned QMA light SepPak cartridge, an OASIS MCX SepPak cartridge, and a custom packed size exclusion cartridge (2 mL, Supelco, Cat.
• FIG. 26 shows the cassette layout of FIG. 26.
• the radiosynthesis of 2 was performed as described in Example 15. After priming the Sephadex cartridge with saline (5 mL), the crude reaction mixture was pumped through the Sephadex cartridge and pure 2 collected in the product vial. The synthesis time was 40 minutes and the non-decay corrected radiochemical yield was 10 %. The radiochemical purity of the product was 95 % and the level of DMAB was 0.8 ⁇ g/mL.
• FIG. 27 shows the HPLC analysis of the final product.
• GE Healthcare NAP5 size exclusion cartridge
• FIG. 28 shows the analytical HPLC of the formulated product. Table 11 summarises the data of individual runs.
• N,N"-bis(2-hydroxyethyl)-ethylenediamine (Aldrich, 14.8 g, 100 mmol) and pyridine (Fluka, 200mL) was stirred at 0°C under nitrogen while a solution of toluene-4-sulfonyl chloride (Fluka, 77 g, 400 mmol) dissolved in pyridine (Fluka, lOOmL) was dropped into the solution over a period of 75 minutes. The temperature was slowly raised to room temperature and continued stirred for 4 hours. Solution was poured into a mixture of ice (250 mL) and hydrochloric acid (concentrated, 250 mL) while stirring to afford a dark sticky oil.
• Tetratosyl-N,N -bis(2-hydroxyethyl)ethylene diamine See Example 17a(i)(a); 2.0 g, 2.6 mmol), benzyl amine (500 ⁇ 1, 4.6 mmol), potassium carbonate (Fluka, 792 mg, 5.7 mmol) and acetonitrile (Merck, 25 mL) was heated to 100°C and stirred overnight. Solvents were removed from solid product by filtration. The solid was washed with acetonitrile (2x 10 mL) and solvents were evaporated off. Solids was dissolved in hot ethanol (15 mL) and left for three days in room temperature. Crystals were collected by filtration and dried in vacuum overnight.
• NOTA(bis-tBu) was purified by preparative HPLC (gradient: 20-40% B over 40 min) affording 72 mg pure NOTA(bis-tBu).
• the purified material was characterised by LC-MS (gradient: 10-40% B over 5): i R : 3.75 min, found m/z: 416.2, expected MH + : 416.3.
• N-(2-Aminoethyl)maleimide trifluoroacetic acid salt 23 mg, 0.090 mmol
• NOTA(bis-tBu) 30 mg, 0.072 mmol
• PyAOP 51 mg, 0.10 mmol
• DMF ⁇ , ⁇ -dimethylformamide
• Sym.-collidine 29 ⁇ L ⁇ , 0.40 mmol
• the mixture was diluted with water/0.1 % trifluoroacetic acid (TFA) (6 mL) and the product purified by semi- preparative HPLC.
• NOTA(bis-tBu)-maleimide 33 mg, 61 ⁇ was treated with a solution of 2.5% triisopropylsilane (TIS) and 2.5% water in TFA (10 mL) for 4 hrs 30 min. TFA was evaporated in vacuo, the residue dissolved in water/0.1 % TFA (8 mL) and the product purified by semi-preparative HPLC. Purification using semi-preparative HPLC (gradient: 0-20% B over 40 min) afforded 15 mg (58%) pure NOTA(bis-acid)- maleimide. The purified material was characterised by LC-MS (gradient: 0-30% B over 5): i R : 1.34 min, found m/z 426.0, expected MH + : 426.2
• Recombinant Z02891-Cys 40 mg, 5.7 ⁇ (purchased from Affibody AB, Sweden) and NOTA(bis-acid)-maleimide (6.1 mg, 14 ⁇ ) were dissolved in water (1.5 mL). The solution was adjusted to pH 6 by adding ammonium acetate and the mixture shaken for 1 nr. The reaction mixture was diluted with water/0.1 % TFA (6 mL) and the product purified using semi-preparative HPLC. Purification using semi- preparative HPLC (gradient: 20-30% B over 40 min) afforded 38 mg (90%) pure compound 4. Purified 4 was analysed by analytical LC-MS (gradient: 10-40% B over 5 min): 3 ⁇ 4: 3.31 min, found m/z: 1864.5, expected MH 4 4+ : 1864.5
• Fluorine- 18 was purified using a QMA cartridge and eluted with saline as described by W. J. McBride et al. (Bioconj. Chem. 2010, 21, 1331). A solution of 18 F- water (25 ⁇ L, 12 MBq) was mixed with AICI 3 (1.667 ⁇ g, 12.5 nmol) in sodium acetate buffer (1.5 ⁇ L, pH 4.0, 0.5 M) and compound 6 (380 ⁇ g, 50 nmol):
• NOTA(tris-tBu)-NH-CH 2 CH 2 -NH 2 (123 mg, 0.176 mmol), 3-maleimido- propionic aid NHS ester (70 mg, 0.26 mmol) and sym.-collidine (346 ⁇ L ⁇ , 2.60 mmol) were dissolved in NMP (2 mL). The reaction mixture was stirred for 6 hr. Water (6 mL) was added and the product purified by semi-preparative HPLC. Purification using semi-preparative HPLC (gradient: 20-50% B over 40 min) afforded 115 mg (87%) pure NOTA(tris-tBu)-NH-CH 2 CH 2 -NH-maleimide. The purified material was characterised by LC-MS (gradient: 10-60% B over 5): 3 ⁇ 4: 3.36 min, found m/z: 737.4, expected MH + : 737.4
• NOTA(tris-tBu)-NH-CH 2 CH 2 -NH-maleimide (115 mg, 0.150 mmol) was treated with a solution of 2.5% TIS and 2.5% water in TFA (10 mL) for 4 hrs. The solvents were evaporated in vacuo, the residue re-dissolved in water (8 mL) and the product purified by semi-preparative HPLC. Purification using semi-preparative HPLC (gradient: 0-20% B over 40 min) afforded 80 mg (90%) pure NOTA(tris-acid)- NH-CH 2 CH 2 -NH-maleimide. The purified material was characterised by LC-MS (gradient: 0-30% B over 5): t R : 2.1 min, found m/z: 569.5, expected MH + : 569.2
• EAKYAKEMRNAYWEIALLPNLTNQQKRAFIRKLYDDPSQSSELLSEAKKLND SQAPKVDC was assembled on a CEM Liberty microwave peptide synthesiser using Fmoc chemistry starting with 0.05 mmol NovaPEG Rink Amide resin. 0.5 mmol amino acid was applied in each coupling step (5 min at 75 °C) using 0.45 mmol HBTU/0.45 mmol HO At/ 1.0 mmol DIPEA for in situ activation. Fmoc was removed by 5% piperazine in DMF. Double coupling of both Arg was applied. Asp-Ser and Leu-Ser pseudoproline dipeptides (0.5 mmol) were incorporated into the sequence.
• Example 20 Impact of the rea2ent dilution on radiochemical yields of ri8F]AlF-NOTA(COOH)2-Z02891(SEO ID No. 2)(5)
• a small volume of [ 18 F]fluoride (10 ⁇ ,, 80 MBq) was added. Two serial dilutions of this mixture (50 % and 25 % v/v) with sodium acetate buffer (1.5 ⁇ L ⁇ , pH 4.0, 0.5 M) were prepared.
• Example 21 Impact of the peptide/AlC13 concentration on radiochemical yields of ri8FlAlF-NOTA(COOH 2-Z02891(SEO ID No. 2X5)
• Example 22 Impact of microwave heatin2 on radiochemical yields of r 18 FlAlF-NOTA(COOH),-Z02891(SEO ID No. 2X5)
• a PP centrifuge vial 1.5 mL containing [ ls F]fluoride (25 ⁇ ,, 29 MBq), A1C1 3 (1.66 ⁇ g, 12.5 nmol) in 1.5 sodium acetate buffer, pH 4.0, 0.5 M), and 6 (380 ⁇ g, 50 nmol) in sodium acetate buffer (25 ⁇ , pH 4.0, 0.5 M) was heated at 100 °C for 15 minutes.
• the analytical RCY of 5a was 15-20 %.
• FIG. 31 shows the HPLC profile of the reaction mixture.
• FIG. 32 shows the HPLC analysis of the final product.
• Example 25 Tumour model validation
• the A431 and NCI-N87 xenograft models were validated for tumour growth and HER2 expression.
• the animal model setup involved inoculation of 2xl0 6 NCI- N87 or 10 7 A431 cells per animal (in ⁇ of 50%PBS/50%Matrigel) subcutaneously into the right flank followed by an inoculation period of 30 days.
• HER2 expression in these tumours was assessed by immunohistochemistry, using the FDA-validated HercepTest (Dako, K5204).
• FIG. 33 depicts that with the recommended intensity scale (0 -> +3), NCI-N87 tumours stain strongly (+3), while A431 cells show a considerably weaker staining intensity (+1).
• Example 28 Imaging of 2 in dual tumour xeno2raft model
• Dual tumour xenograft mice were generated by implantation of A431 and NCI-N87 in each of the two flanks. These mice were used to assess the biodistribution of 2, enabling a same-animal assessment of uptake in both low and high HER2 expressing tumours. Timepoints included 30 and 60 p.i.
• FIG. 36 shows that 2 performance was comparable to that observed in the single tumour animal studies, with good separation in binder uptake between the A431 and NCI-N87 tumours, starting from as early as 30min p.i.
• background tissue clearance see Table 7 for key tissue ratios
• blood levels at 60min p.i. have reduced significantly, providing a NCI-N87 tumour: blood ratio of 4.52
• partial blood clearance gives a 2.39 ratio, accompanied by a positive tumounliver ratio of 1.39.
• the concentration of cold precursor in the standard preparation was 12C ⁇ g/kg per mouse, therefore this study examined the effects of cold precursor at 10 x the original concentration used (in the mouse).
• FIG. 37 shows that the effect on tumour uptake was not significant and clearance from other tissues was not significantly affected either.
• Example 30 Compound 2 in vivo imaging studies in dual flank A431/NCI-N87 tumoured mice
• the dual-tumour mouse model described in Example 28 was used to perform a preliminary imaging study. 10 MBq of 2 were injected i.v. per animal and the mice were imaged for 30 minutes starting at 120 min p.i. The image in FIG 38 shows that clearance was through the kidneys and bladder, as previously demonstrated through the biodistribution studies. The transverse imaging shows uptake in the 2 tumours, with the NCI-N87 tumour showing considerably higher signal intensity than the A431 tumour, in agreement with the dual tumour biodistribution studies in Example 28.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Optics & Photonics (AREA)
• Animal Behavior & Ethology (AREA)
• Cell Biology (AREA)
• Physics & Mathematics (AREA)
• Zoology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Toxicology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Oncology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nuclear Medicine (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=45444771

Family Applications (4)

Family Applications Before (2)

Family Applications After (1)

Country Status (13)

Families Citing this family (20)

Family Cites Families (13)

• 2011
  • 2011-12-19 KR KR1020187010276A patent/KR20180042442A/ko active Application Filing
  • 2011-12-19 SG SG2013048061A patent/SG191292A1/en unknown
  • 2011-12-19 JP JP2013546277A patent/JP2014503546A/ja active Pending
  • 2011-12-19 CA CA2822815A patent/CA2822815A1/en not_active Abandoned
  • 2011-12-19 BR BR112013015796A patent/BR112013015796A2/pt not_active IP Right Cessation
  • 2011-12-19 MX MX2013007365A patent/MX2013007365A/es not_active Application Discontinuation
  • 2011-12-19 NZ NZ612312A patent/NZ612312A/en not_active IP Right Cessation
  • 2011-12-19 CN CN201180068114.4A patent/CN103533963B/zh not_active Expired - Fee Related
  • 2011-12-19 EP EP21190695.3A patent/EP3936155A1/en active Pending
  • 2011-12-19 KR KR1020217014930A patent/KR102498607B1/ko active IP Right Grant
  • 2011-12-19 RU RU2013128358/10A patent/RU2592685C2/ru active
  • 2011-12-19 EP EP21190694.6A patent/EP3957332A1/en active Pending
  • 2011-12-19 KR KR1020237004408A patent/KR20230034403A/ko not_active Application Discontinuation
  • 2011-12-19 MX MX2013007371A patent/MX2013007371A/es unknown
  • 2011-12-19 BR BR112013015786-0A patent/BR112013015786A2/pt not_active IP Right Cessation
  • 2011-12-19 NZ NZ612161A patent/NZ612161A/en unknown
  • 2011-12-19 JP JP2013546278A patent/JP2014507400A/ja active Pending
  • 2011-12-19 EP EP11804897.4A patent/EP2654804A1/en not_active Withdrawn
  • 2011-12-19 CA CA3159948A patent/CA3159948A1/en active Pending
  • 2011-12-19 KR KR1020137019088A patent/KR20130132935A/ko not_active Application Discontinuation
  • 2011-12-19 KR KR1020137019116A patent/KR20140045312A/ko active Search and Examination
  • 2011-12-19 AU AU2011349482A patent/AU2011349482A1/en not_active Abandoned
  • 2011-12-19 EP EP11804895.8A patent/EP2654803B1/en active Active
  • 2011-12-19 CA CA2822693A patent/CA2822693C/en active Active
  • 2011-12-19 SG SG2013047725A patent/SG191270A1/en unknown
  • 2011-12-19 WO PCT/US2011/065777 patent/WO2012096760A1/en active Application Filing
  • 2011-12-19 RU RU2013128361/10A patent/RU2013128361A/ru not_active Application Discontinuation
  • 2011-12-19 WO PCT/US2011/065794 patent/WO2012087908A1/en active Application Filing
  • 2011-12-19 AU AU2011354599A patent/AU2011354599B2/en active Active
• 2013
  • 2013-06-17 IL IL227003A patent/IL227003A/en active IP Right Grant

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events